Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

MedAlert Tag: marijuana

DEA to Reschedule Marijuana

April 30, 2024

The DEA announced plans to reschedule marijuana from a Schedule I drug to a Schedule III drug. Rescheduling marijuana would not make it legal for recreational use, as Schedule III drugs are still controlled substances and subject to rules and regulations. However, this proposal recognizes the medical uses of cannabis and acknowledges that cannabis has less potential for abuse than other drugs. Clinical research has found that marijuana has the potential to assist with the treatment of chronic pain, neuropathic pain, spasticity, PTSD, depression, and anxiety. Much opposition to the use of medical marijuana in workers’ comp has been tied to federal restrictions, which will soon be lifted; this could result in greater utilization of medical marijuana. The DEA’s proposal will first be reviewed by the White House Office of Management and Budget. Once the White House signs off on the proposal, the DEA will hold a 60-day public comment period, after which it will be reviewed by an administrative judge. After this, the DEA would publish the final rule.

Read More
lockenvelopephone-handsetmagnifiermenucross-circle